Πſ IUPUI **DEPARTMENT OF BIOMEDICAL** ENGINEERING

Skeletal Manifestations in a Streptozotocin-Induced Mouse Model of Diabetes

Background

Diabetes and Bone

- \hat{V} Advanced Glycation End Products (AGEs)
- \bigwedge Ca²⁺, Vitamin D •
- $\hat{\mathbf{v}}$ PTH, inflammatory cytokines
- BMD •
- $\hat{\mathbf{v}}$ Risk of fracture •

Streptozotocin (STZ)

- Competitively inhibits glucose
- High toxicity with specificity to pancreatic β -cells
- Highly unstable, injectable when dissolved in buffer pH ~4.5

AIM: Characterize the bone phenotype resulting from sustained hyperglycemia in male and female mice.

Methods

Study Design

- C57Bl/6J mice
- 4 groups, n = 15/group







90 mg/kg,

citrate buffeı

Male Ctrl

Vehicle Only



Male STZ 65 mg/kg, citrate buffer

• IP injection, 5 consecutive days @ 8 weeks old

Glucose Measurements

- Fasted Glucose Tolerance Testing
- N = 7 / group
- 12+ hr. fast
- 2g/kg glucose bolus
- Fasted Insulin Tolerance Testing
- N = 8 / group
- 2 hr. fast
- Weekly Non-fasted Blood Glucose 0.75 U/kg insulin bolus



Microcomputed Tomography (µCT)

- 0.5 m Al filter (V = 60 kV, I = 167 μ A)
- 9.8 μm/voxel resolution
- 0.7 degree interval
- 1-mm cortical region selected

Statistical Analysis

- 2 way ANOVA (p < 0.05) for main effects of treatment and sex with post-hoc Tukey's HSD evaluation when significant interaction found
- All data mean +/- SD

Hemoglobin A1C Analysis

- Blood collected via cardiac exsanguination
- Latex Agglutination Inhibition Assay
- Reported as <u>glycated hemoglobin</u> total hemoglobin

Pancreatic Analysis

- Fixed in formalin
- Embedded in paraffin
- Insulin positive area stained

fAGE Analysis

- N = 5/group, random sampling
- Demineralized, dried, digested (6 M/mg HCL, 110°, 20 hrs.)
- Fluoresced @ 360 nm excitation and 460 nm emission
- Tested against quinine standard, normalized to collagen content (via hydroxyproline)



Jennifer Hatch, Dyann Segvich, Rachel Kohler, Joseph Wallace

Department of Biomedical Engineering Indiana University – Purdue University Indianapolis

Results

- M. Ctrl - M. STZ - F. Ctrl - F. STZ







Figure 3. STZ mice have less mass than control animals and Female STZ mice have shorter tibiae than controls similar to patients with childhood onset Type 1 Diabetes (A,B). Both trabecular thickness and cortical area are is significantly less in STZ females suggesting dysregulation of the bone modeling system (C, E). Both lower cortical area and lower marrow area drive a lower percent bone area in treated animals (G). TMD in both types of bone vary significantly with sex and disease (D, H).







B). All STZ-treated animals underwent less work before yield and failure (C,D). The reduced ability to withstand force is represented as a significantly reduced stiffness in treated female bones (E). On a material level, yield and ultimate stresses were lower in STZ mice leading to a modulus which was reduced in STZ-treated bones of both sexes (F, G, H).

Conclusions

- STZ treatment successfully induced diabetic state Skeletal manifestations paralleled clinical diabetic outcomes
- Reduced BMD, compromised bone quality, and reduced longitudinal growth.
- Useful model for study of diabetic bone
- Future Work:

1.25

- Extend age of mice to explore effects in aging population,
- Explore effect of loading on bone in STZ mice,
- Combine with other clinically relevant disease models.



